Efficacy and safety of inorganic nitrate/nitrite supplementary therapy in heart failure with preserved ejection fraction
BackgroundApproximately half of patients with heart failure have a preserved ejection fraction (HFpEF). To date, only SGLT-2i, ARNi, and MRAs treatments have been shown to be effective for HFpEF. Exercise intolerance is the primary clinical feature of HFpEF. The aim of this meta-analysis was to expl...
Main Authors: | Feng Lv, Junyi Zhang, Yuan Tao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1054666/full |
Similar Items
-
Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
by: Rahul N. Patel, et al.
Published: (2023-12-01) -
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01) -
Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest
by: Alberto Palazzuoli, et al.
Published: (2023-01-01) -
Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey
by: Magdy Abdelhamid, et al.
Published: (2023-10-01) -
The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
by: Becker Al-Khayatt, et al.
Published: (2024-05-01)